Sangamo BioSciences | SGMO - Sales Revenues


Sangamo BioSciences reported $356K in Sales Revenues for its fiscal quarter ending in June of 2024.





Sales Change Date
Alaunos Therapeutics USD 2K 2K Mar/2025
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
Alterity Therapeutics Limited AUD 596.04K 584.66K Dec/2025
Amgen USD 9.9B 340M Dec/2025
Bayer EUR 11.44B 1.78B Dec/2025
BioCryst Pharmaceuticals USD 406.56M 247.16M Dec/2025
Biogen USD 2.28B 250M Dec/2025
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Cipla INR 75.18B 710M Dec/2025
Clal Biotechnology ILS 3.41M 2M Dec/2022
Compugen USD 67.33M 65.44M Dec/2025
CSL USD 8.33B 4.79B Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Grifols EUR 2.34B 33.3M Mar/2026
Ionis Pharmaceuticals USD 203M 46M Dec/2025
J&J USD 24.1B 500M Mar/2026
Karyopharm Therapeutics USD 34.08M 3.54M Dec/2025
Merck USD 16.4B 880M Dec/2025
Novartis USD 13.86B 50M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sangamo BioSciences USD 356K 125K Jun/2024
Sanofi EUR 11.3B 1.13B Dec/2025
Sarepta Therapeutics USD 442.9M 43.5M Dec/2025
Tectonic Therapeutic USD 0 0 Dec/2024
Ultragenyx Pharmaceutical USD 207M 47M Dec/2025
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025